Reuters: Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery Peer-reviewed
Eli Lilly's $2.75 Billion AI Drug Discovery Bet: What It Means for Longevity Clinics and Patients
Eli Lilly signed a $2.75B deal with Insilico Medicine for AI-generated drug candidates targeting age-related diseases. Big Pharma is now investing billions in longevity drug discovery. Here's what it means for clinics and patients.